Oshtoran Syndrome and the H63D Syndrome Family

Oshtoran Syndrome and the H63D Syndrome Family An official information sheet for treating physicians, patients, and families Oshtoran Syndrome – sometimes referred to in the international scientific community as H63D Syndrome Type 3 – is a rare but clinically and molecularly well-documented disorder belonging to the broader group of H63D syndromes. This group is based on a homozygous mutation of the HFE gene (H63D/H63D), though it has no connection to classic hemochromatosis. The disease mechanisms is entirely different. The pathophysiology of Oshtoran Syndrome has been known for quite a while now and is strictly based on three core pillars: A homozygous H63D mutation that leads to hypotransferrinemia, consistently high transferrin saturation, and simultaneously relatively or significantly decreased ferritin. The resulting non-transferrin-bound iron (NTBI) is highly toxic and deposits in tissue – particularly parenchymal organs, the heart, and the brain, especially in the substantia nigra and basal ganglia. As of 2025, no method exists to safely remove NTBI from the body; attempts at iron chelation can result in fatal ferritin depletion before meaningful NTBI reduction is achieved. A mitochondrial dysregulation, typically X-linked (thus affecting almost exclusively males), leading to ATP deficiency and resulting in functional disturbances across nearly all cell types. A “second hit” scenario, typically triggered by a severe infection, trauma, major stress, or hormonal transition, which causes clinical manifestation of the syndrome. • Oshtoran Syndrome is incurable, progressive, and potentially affects all organ systems.• The primary problem is a slow but continuous breakdown of physiological homeostasis. Autonomic regulation, glandular control, hormonal axis integration with potential lethal consequnces.• Innate immune system function become increasingly dysregulated – often with catastrophic consequences. Which symptoms appear and in what sequence is highly individual. The symptom spectrum is broad, but clinically consistent and logical within the framework of the syndrome.